JP2005519080A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005519080A5 JP2005519080A5 JP2003570902A JP2003570902A JP2005519080A5 JP 2005519080 A5 JP2005519080 A5 JP 2005519080A5 JP 2003570902 A JP2003570902 A JP 2003570902A JP 2003570902 A JP2003570902 A JP 2003570902A JP 2005519080 A5 JP2005519080 A5 JP 2005519080A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- inhibitors
- pyrimidin
- delivery device
- drug delivery
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000004663 cell proliferation Effects 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 3
- 230000006907 apoptotic process Effects 0.000 claims description 3
- 230000012292 cell migration Effects 0.000 claims description 3
- 230000008021 deposition Effects 0.000 claims description 3
- 239000011159 matrix material Substances 0.000 claims description 3
- 238000013508 migration Methods 0.000 claims description 3
- 210000000329 smooth muscle myocyte Anatomy 0.000 claims description 3
- -1 4-Methyl-piperazino-methyl Chemical group 0.000 claims 8
- 239000003795 chemical substances by application Substances 0.000 claims 8
- 150000003839 salts Chemical group 0.000 claims 8
- 238000012377 drug delivery Methods 0.000 claims 7
- 230000002792 vascular Effects 0.000 claims 7
- 239000003112 inhibitor Substances 0.000 claims 6
- 206010016717 Fistula Diseases 0.000 claims 5
- 239000013078 crystal Chemical group 0.000 claims 5
- 230000004064 dysfunction Effects 0.000 claims 5
- 230000003890 fistula Effects 0.000 claims 5
- 238000003780 insertion Methods 0.000 claims 5
- 230000037431 insertion Effects 0.000 claims 5
- 230000002265 prevention Effects 0.000 claims 5
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 4
- 239000003102 growth factor Substances 0.000 claims 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 4
- 229940079593 drug Drugs 0.000 claims 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 3
- 229960002930 sirolimus Drugs 0.000 claims 3
- 238000011287 therapeutic dose Methods 0.000 claims 3
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 claims 2
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 102000036530 EDG receptors Human genes 0.000 claims 2
- 108091007263 EDG receptors Proteins 0.000 claims 2
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 2
- 102000003960 Ligases Human genes 0.000 claims 2
- 108090000364 Ligases Proteins 0.000 claims 2
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 2
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 2
- 229960002478 aldosterone Drugs 0.000 claims 2
- 230000001028 anti-proliverative effect Effects 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 229940111134 coxibs Drugs 0.000 claims 2
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 210000003038 endothelium Anatomy 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000004698 lymphocyte Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 claims 2
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 claims 2
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims 2
- 229960005330 pimecrolimus Drugs 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 229940044601 receptor agonist Drugs 0.000 claims 2
- 230000008929 regeneration Effects 0.000 claims 2
- 238000011069 regeneration method Methods 0.000 claims 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 2
- LQHQKYWYKPLKCH-UHFFFAOYSA-N 4-pyridin-3-ylpyrimidin-2-amine Chemical compound NC1=NC=CC(C=2C=NC=CC=2)=N1 LQHQKYWYKPLKCH-UHFFFAOYSA-N 0.000 claims 1
- 102000015427 Angiotensins Human genes 0.000 claims 1
- 108010064733 Angiotensins Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 102100028255 Renin Human genes 0.000 claims 1
- 108090000783 Renin Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 229940046731 calcineurin inhibitors Drugs 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000015271 coagulation Effects 0.000 claims 1
- 238000005345 coagulation Methods 0.000 claims 1
- 238000000502 dialysis Methods 0.000 claims 1
- 238000001631 haemodialysis Methods 0.000 claims 1
- 230000000322 hemodialysis Effects 0.000 claims 1
- 238000009434 installation Methods 0.000 claims 1
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 1
- 229960000951 mycophenolic acid Drugs 0.000 claims 1
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 1
- 235000016236 parenteral nutrition Nutrition 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 230000036454 renin-angiotensin system Effects 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36025402P | 2002-02-28 | 2002-02-28 | |
| PCT/EP2003/002028 WO2003072159A1 (en) | 2002-02-28 | 2003-02-27 | N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005519080A JP2005519080A (ja) | 2005-06-30 |
| JP2005519080A5 true JP2005519080A5 (https=) | 2006-05-25 |
Family
ID=27766209
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003570902A Pending JP2005519080A (ja) | 2002-02-28 | 2003-02-27 | Ｎ−｛５−［４−（４−メチル−ピペラジノ−メチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリミジン−アミン被覆ステント |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050209244A1 (https=) |
| EP (1) | EP1480688A1 (https=) |
| JP (1) | JP2005519080A (https=) |
| KR (1) | KR20040093058A (https=) |
| CN (1) | CN1326577C (https=) |
| AU (1) | AU2003214079B2 (https=) |
| BR (1) | BR0308053A (https=) |
| CA (1) | CA2477558A1 (https=) |
| CO (1) | CO5611172A2 (https=) |
| EC (1) | ECSP045240A (https=) |
| IL (1) | IL163771A0 (https=) |
| MX (1) | MXPA04008361A (https=) |
| NO (1) | NO20044093L (https=) |
| NZ (1) | NZ534544A (https=) |
| PL (1) | PL371466A1 (https=) |
| RU (1) | RU2341266C2 (https=) |
| WO (1) | WO2003072159A1 (https=) |
| ZA (1) | ZA200406191B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399480B2 (en) | 1997-09-26 | 2008-07-15 | Abbott Laboratories | Methods of administering tetrazole-containing rapamycin analogs with other therapeutic substances using medical devices |
| TW200306826A (en) * | 2002-01-10 | 2003-12-01 | Novartis Ag | Drug delivery systems for the prevention and treatment of vascular diseases |
| AU2003232115A1 (en) * | 2002-05-13 | 2003-11-11 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
| CA2439440A1 (en) * | 2002-09-05 | 2004-03-05 | Emory University | Treatment of tuberous sclerosis associated neoplasms |
| FR2846886A1 (fr) * | 2002-11-08 | 2004-05-14 | Merck Sante Sas | Utilisation de fosinopril pour diminuer les evenements cardiovasculaires chez des patients dialyses |
| JP2006526652A (ja) * | 2003-06-03 | 2006-11-24 | ベス・イスラエル・ディーコニス・メディカル・センター | 血管狭窄を治療するための方法及び化合物 |
| CA2538999A1 (en) * | 2003-09-19 | 2005-03-31 | Children's Hospital Medical Center | Regulation of cardiac contractility and heart failure propensity |
| CA2538523A1 (en) * | 2003-09-19 | 2005-03-31 | Novartis Ag | Treatment of gastrointestinal stromal tumors with imatinib and midostaurin |
| US20090232866A1 (en) * | 2003-10-07 | 2009-09-17 | Mariann Pavone-Gyongyosi | Oligopeptides as coating material for medical products |
| US8101199B2 (en) | 2003-10-21 | 2012-01-24 | Celonova Biosciences, Inc. | Des-methyl-tocopherol therapy for restenosis prevention |
| WO2005049021A1 (en) * | 2003-11-03 | 2005-06-02 | Oy Helsinki Transplantation R & D Ltd | Materials and methods for inhibiting neointimal hyperplasia |
| CN1878579A (zh) * | 2003-11-07 | 2006-12-13 | 拜克技术有限公司 | 制备药物洗脱医疗器械的方法和由该方法得到的医疗器械 |
| US7959659B2 (en) | 2004-01-02 | 2011-06-14 | Advanced Cardiovascular Systems, Inc. | High-density lipoprotein coated medical devices |
| MX2007002415A (es) * | 2004-08-31 | 2007-04-23 | Novartis Ag | Uso de midostaurina para el tratamiento de tumores estromales gastrointestinales. |
| WO2007011707A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Polymer coatings containing drug powder of controlled morphology |
| WO2007011708A2 (en) | 2005-07-15 | 2007-01-25 | Micell Technologies, Inc. | Stent with polymer coating containing amorphous rapamycin |
| US20090304766A1 (en) * | 2005-11-30 | 2009-12-10 | Lawrence Mayer | Localized delivery of drug combinations |
| CA2996768C (en) | 2006-04-26 | 2020-12-08 | Micell Technologies, Inc. | Coatings containing multiple drugs |
| US8088789B2 (en) | 2006-09-13 | 2012-01-03 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| EP2083834B1 (en) * | 2006-09-13 | 2017-06-21 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US10695327B2 (en) | 2006-09-13 | 2020-06-30 | Elixir Medical Corporation | Macrocyclic lactone compounds and methods for their use |
| US11426494B2 (en) | 2007-01-08 | 2022-08-30 | MT Acquisition Holdings LLC | Stents having biodegradable layers |
| CA2679712C (en) | 2007-01-08 | 2016-11-15 | Micell Technologies, Inc. | Stents having biodegradable layers |
| SG192523A1 (en) | 2008-04-17 | 2013-08-30 | Micell Technologies Inc | Stents having bioabsorbable layers |
| US9510856B2 (en) | 2008-07-17 | 2016-12-06 | Micell Technologies, Inc. | Drug delivery medical device |
| EP2313122B1 (en) | 2008-07-17 | 2019-03-06 | Micell Technologies, Inc. | Drug delivery medical device |
| EP2352459A4 (en) * | 2008-10-03 | 2013-09-25 | Elixir Medical Corp | MACROCYCLIC LACTON COMPOUNDS AND METHOD FOR THEIR USE |
| AU2010200316A1 (en) * | 2009-01-30 | 2010-08-19 | Cordis Corporation | Reservoir Eluting Stent |
| WO2010120552A2 (en) | 2009-04-01 | 2010-10-21 | Micell Technologies, Inc. | Coated stents |
| WO2010121187A2 (en) | 2009-04-17 | 2010-10-21 | Micell Techologies, Inc. | Stents having controlled elution |
| US11369498B2 (en) * | 2010-02-02 | 2022-06-28 | MT Acquisition Holdings LLC | Stent and stent delivery system with improved deliverability |
| CA2797110C (en) | 2010-04-22 | 2020-07-21 | Micell Technologies, Inc. | Stents and other devices having extracellular matrix coating |
| EP2593039B1 (en) | 2010-07-16 | 2022-11-30 | Micell Technologies, Inc. | Drug delivery medical device |
| US10117972B2 (en) | 2011-07-15 | 2018-11-06 | Micell Technologies, Inc. | Drug delivery medical device |
| BR112014008241A2 (pt) * | 2011-10-07 | 2017-04-18 | Cellzome Ltd | composto, composição farmacêutica, métodos para tratar, controlar, retardar ou prevenir doenças e distúrbios, e para preparar um composto, e, uso de um composto |
| US10188772B2 (en) | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| US9364273B2 (en) | 2012-08-15 | 2016-06-14 | DePuy Synthes Products, Inc. | Drug eluting surgical screw |
| AU2014248508B2 (en) | 2013-03-12 | 2018-11-08 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
| WO2014186532A1 (en) | 2013-05-15 | 2014-11-20 | Micell Technologies, Inc. | Bioabsorbable biomedical implants |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0533816B1 (en) * | 1990-06-15 | 1995-06-14 | Cortrak Medical, Inc. | Drug delivery apparatus |
| TW225528B (https=) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
| US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| US5569198A (en) * | 1995-01-23 | 1996-10-29 | Cortrak Medical Inc. | Microporous catheter |
| ZA9710342B (en) * | 1996-11-25 | 1998-06-10 | Alza Corp | Directional drug delivery stent and method of use. |
| CO4940418A1 (es) * | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| WO2000009098A2 (en) * | 1998-08-13 | 2000-02-24 | Novartis Ag | Method for treating ocular neovascular diseases |
-
2003
- 2003-02-27 MX MXPA04008361A patent/MXPA04008361A/es unknown
- 2003-02-27 US US10/505,398 patent/US20050209244A1/en not_active Abandoned
- 2003-02-27 NZ NZ534544A patent/NZ534544A/en unknown
- 2003-02-27 KR KR10-2004-7012608A patent/KR20040093058A/ko not_active Ceased
- 2003-02-27 CN CNB038047888A patent/CN1326577C/zh not_active Expired - Fee Related
- 2003-02-27 WO PCT/EP2003/002028 patent/WO2003072159A1/en not_active Ceased
- 2003-02-27 PL PL03371466A patent/PL371466A1/xx not_active Application Discontinuation
- 2003-02-27 IL IL16377103A patent/IL163771A0/xx unknown
- 2003-02-27 EP EP03709729A patent/EP1480688A1/en not_active Withdrawn
- 2003-02-27 RU RU2004129281/15A patent/RU2341266C2/ru not_active IP Right Cessation
- 2003-02-27 BR BR0308053-6A patent/BR0308053A/pt not_active IP Right Cessation
- 2003-02-27 JP JP2003570902A patent/JP2005519080A/ja active Pending
- 2003-02-27 AU AU2003214079A patent/AU2003214079B2/en not_active Ceased
- 2003-02-27 CA CA002477558A patent/CA2477558A1/en not_active Abandoned
-
2004
- 2004-08-03 ZA ZA200406191A patent/ZA200406191B/en unknown
- 2004-08-20 EC EC2004005240A patent/ECSP045240A/es unknown
- 2004-09-21 CO CO04093663A patent/CO5611172A2/es not_active Application Discontinuation
- 2004-09-27 NO NO20044093A patent/NO20044093L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005519080A5 (https=) | ||
| RU2004129281A (ru) | Стенты с нанесенным покрытием, содержащим n-{5-[4-(4-метилпиперазинометил)бензоиламидо]-2-метилфенил}-4-(3- пиридил)- 2-пири мидинамин | |
| RU2004124387A (ru) | Системы введения лекарственных средств, содержащих рапамицин и его производные, которые предназначены для предупреждения и лечения сосудистых заболеваний | |
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| RU2519660C2 (ru) | Режим дозировки селективного агониста рецептора s1p1 | |
| Hahnenkamp et al. | Regional anaesthesia, local anaesthetics and the surgical stress response | |
| WO2009129210A4 (en) | Compositions and methods for treating post-operative pain using clonidine and bupivacaine | |
| JP2005527535A5 (https=) | ||
| JP2019505585A (ja) | ２−ブロモ−１−（３，３−ジニトロアゼチジン−１−イル）エタノンの静脈内投与のための組成物および方法 | |
| RU2019100037A (ru) | Способ лечения рассеянного склероза с использованием ингибитора lsd1 | |
| ES3041145T3 (en) | New oral pharmaceutical composition and dose regimen for the therapy of progressive fibrosing interstitial lung diseases | |
| JP2002534477A (ja) | メラガトランの新規使用 | |
| JPWO2021260111A5 (https=) | ||
| CN1625402A (zh) | 4－(2－氟苯基)－6－甲基－2－(1－哌嗪基)噻吩并(2,3－d)－嘧啶用于治疗尿失禁的用途 | |
| JP5547487B2 (ja) | 抗癌化合物の投与方法 | |
| JP5303093B2 (ja) | テナトプラゾール及びヒスタミンｈ２受容体拮抗剤を組み合わせた医薬組成物 | |
| EP1203585B1 (en) | Anti-ischemic agent | |
| JP4855073B2 (ja) | 併用医薬 | |
| JP2021533107A (ja) | 癌を治療するための併用療法 | |
| JP2019001830A (ja) | 医薬 | |
| KR930007249B1 (ko) | 뇌혈관 수축 치료제 | |
| CN119587550A (zh) | 氟马替尼在制备治疗肺动脉高压药物中的应用 | |
| JP2009521513A (ja) | 治療の方法 | |
| ES2379829T3 (es) | Cicatrización de heridas y úlceras mediada por isoniazida | |
| RU2021130172A (ru) | Способы лечения пограничного расстройства личности |